Identifai Genetics Will List on ASX October 13
The Israeli biotech plans a $10 million IPO to fund research into its fetal genetic screening test.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Do you trust that new prenatal genetic testing technologies provide more medical benefits than risks?
Identifai Genetics will debut on the Australian stock exchange on October 13, 2026, with an initial market capitalization of $38.4 million. The company is raising $10 million to support the development of its prenatal diagnostic technology.
Why it matters
The company aims to shift the medical standard of care by enabling the treatment of inherited conditions before symptoms emerge. This IPO provides capital for its ongoing clinical validation efforts in the United States.
The Windrose test screens for 280 inherited conditions by analyzing cell-free DNA from a maternal blood draw taken at nine weeks of pregnancy. The platform flags 54 conditions treatable in utero and 267 treatable within the first week of life.
The players
Identifai Genetics
An Israeli biotech firm developing prenatal screening tools that utilize machine learning for full-genome analysis.
Noam Shomron
A professor whose research into fetal genetic screening serves as the foundation for the company's diagnostic test.
The details
The Windrose test relies on a machine learning algorithm designed to differentiate fetal cell-free DNA—fragments of genetic material found in the mother's bloodstream—from the mother's own DNA. By scanning the entire genome for disease-causing mutations, the system identifies potential health complications early. This research, founded by Professor Noam Shomron, seeks to bypass the necessity for more invasive diagnostic procedures currently used in clinical practice.
Timeline
2012: Non-invasive pregnancy tests began being offered.
October 13, 2026: Identifai Genetics will debut on the ASX.
Late 2027: Clinical validation trial is expected to conclude.
The Tech Race
Identifai Genetics is attempting to move past standard chromosomal screenings by testing for 280 distinct inherited conditions. This marks an evolution from the foundational NIPT tests introduced in 2012 toward comprehensive, early-intervention genetic diagnostics.
The Windrose test is not yet available for clinical use, as the company is still conducting a 600-patient validation trial. Patients and practitioners should look for published trial results by late 2027 to assess the test's diagnostic accuracy.
The takeaway
Identifai Genetics is moving to monetize early-stage prenatal screening, moving from research to public equity markets. Investors and clinicians should monitor the 600-patient US clinical trial results expected by late 2027 to verify the efficacy of the Windrose test.
What happens next
The company's 600-patient clinical validation trial in the United States is scheduled to run until late 2027.
Further reading
For more on the rapid scaling of genetic diagnostics, explore our latest coverage in Biotech.
Live Poll
Do you trust that new prenatal genetic testing technologies provide more medical benefits than risks?
